Australian company Alterity Therapeutics has announced positive interim data from the Phase 2 clinical trial of ATH434 in patients with multiple system atrophy.
Alterity Therapeutics reports positive interim data from Multiple System Atrophy trial
July 18, 2024 Latest NewsAustralian BiotechLatest Video
New Stories
-
ENA respiratory secures extension of US funding for novel prophylactic antiviral
September 8, 2024 - - Latest News -
Groups welcome wider access to shingles vaccine for immunocompromised patients
September 6, 2024 - - Latest News -
CSL announces sale of Wuhan plasma collection and fractionation operations
September 5, 2024 - - Latest News -
The 'Week in Review' Podcast - 6 September
September 5, 2024 - - Podcast -
Pfizer-backed initiative boosts Aboriginal and Torres Strait Islander pharmacy leadership
September 5, 2024 - - Latest News -
An increasingly busy ministerial agenda risks squeezing out other issues
September 5, 2024 - - Latest News -
Groups collaborate on the development of new opioid safety toolkit
September 5, 2024 - - Latest News